Myriad Genetics (MYGN) Projected to Post Earnings on Monday

Myriad Genetics (NASDAQ:MYGN) is projected to issue its Q4 2025 results before the market opens on Monday, February 23rd. Analysts expect Myriad Genetics to post earnings of ($0.02) per share for the quarter. Investors may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, February 24, 2026 at 4:00 PM ET.

Myriad Genetics Price Performance

NASDAQ MYGN opened at $4.49 on Monday. The firm’s 50 day moving average is $6.11 and its 200-day moving average is $6.65. The company has a quick ratio of 2.12, a current ratio of 2.33 and a debt-to-equity ratio of 0.32. Myriad Genetics has a 12-month low of $3.76 and a 12-month high of $15.47. The company has a market capitalization of $418.51 million, a PE ratio of -1.04 and a beta of 1.90.

Hedge Funds Weigh In On Myriad Genetics

Hedge funds and other institutional investors have recently made changes to their positions in the company. Jacobs Levy Equity Management Inc. lifted its holdings in shares of Myriad Genetics by 157.0% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,442,912 shares of the company’s stock worth $17,662,000 after acquiring an additional 1,492,405 shares during the period. Kent Lake PR LLC acquired a new position in Myriad Genetics during the second quarter valued at approximately $6,638,000. Federated Hermes Inc. lifted its stake in Myriad Genetics by 103,916.0% during the second quarter. Federated Hermes Inc. now owns 1,122,333 shares of the company’s stock worth $5,960,000 after purchasing an additional 1,121,254 shares during the last quarter. State Street Corp lifted its stake in Myriad Genetics by 19.9% during the fourth quarter. State Street Corp now owns 5,966,567 shares of the company’s stock worth $36,694,000 after purchasing an additional 990,075 shares during the last quarter. Finally, Algert Global LLC acquired a new stake in shares of Myriad Genetics in the 3rd quarter valued at $6,601,000. 99.02% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research firms have weighed in on MYGN. Zacks Research lowered Myriad Genetics from a “hold” rating to a “strong sell” rating in a research report on Monday, January 19th. UBS Group lifted their price objective on shares of Myriad Genetics from $6.00 to $8.00 and gave the stock a “neutral” rating in a research report on Tuesday, November 4th. Piper Sandler dropped their price objective on shares of Myriad Genetics from $9.00 to $8.50 and set an “overweight” rating on the stock in a research report on Tuesday, November 11th. Wells Fargo & Company raised their target price on shares of Myriad Genetics from $6.00 to $6.50 and gave the stock an “equal weight” rating in a research note on Wednesday, November 5th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Myriad Genetics in a research note on Monday, December 29th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have given a Sell rating to the company’s stock. Based on data from MarketBeat, Myriad Genetics presently has a consensus rating of “Hold” and an average price target of $9.44.

About Myriad Genetics

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.